NEW YORK, Dec. 30, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to shareholders. Dear Valued Shareholders, 2024 has been a very productive year for…
